About Keymed Biosciences
Keymed Biosciences Inc. (HKEX: 02162) focuses on the urgent unmet clinical needs, and is committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad.
About Stapokibart
Stapokibart is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), and is the first domestically manufactured IL-4Rα antibody drug granted marketing approval by the NMPA. By targeting IL-4Rα, Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines that trigger type II inflammation. Stapokibart has demonstrated good safety and encouraging efficacy in multiple previous clinical trials, and its treatment of the indication of moderate-to-severe atopic dermatitis in adults, the indication of chronic rhinosinusitis with nasal polyposis and treatment of Seasonal Allergic Rhinitis have been approved for marketing in September 2024, December 2024 and February 2025, respectively.
Company Details
- Employees
- 5
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://en.keymedbio.com/
Keymed Biosciences Questions
Keymed Biosciences's website is https://en.keymedbio.com/
Keymed Biosciences's LinkedIn profile is https://www.linkedin.com/company/keymed-biosciences
Keymed Biosciences has
5 employees.
View email and phone details for 5
employees at Keymed Biosciences.
Keymed Biosciences's industry is
Biotechnology Research
Keymed Biosciences's top competitors are
Legend Biotech,
Colina Secreta Glamping And Villas,
康诺亚生物医药科技(成都)有限公司,
Bio-Thera Solutions,
Acea Therapeutics, Inc,
Canfite Biopharma,
Pricehero Inc.,
Hutchmed,
Shenzhen Healing Biotech Co., Ltd.,
Haisco Pharmaceutical Group Co., Ltd.
Keymed Biosciences's categories are Biotechnology Research
Keymed Biosciences's founding year is 2016
